View:
1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) MAY 29, 1996 T CELL SCIENCES, INC. --------------------- (Exact name of registrant as specified in charter) DELAWARE 0-15006 13-3191702 - ---------------------------- ------------------------ ------------------- (State or other jurisdiction (Commission file number) (IRS employer of incorporation) identification no.) 115 FOURTH AVENUE, NEEDHAM, MA 02194 ------------------------------------ (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code: (617) 433-0771 -------------- 2 Item 5 - Other Events - --------------------- On March 29, 1996 T Cell Sciences, Inc. ("T Cell Sciences" or the "Company") announced changes in its senior management effective immediately: Dr. Una S. Ryan was appointed President and Chief Operating Officer and has been elected to the Board of Directors. Dr. Ryan also will retain her position as Chief Scientific Officer. Mr. James D. Grant will assume the position of Chief Executive Officer, in addition to retaining his position as Chairman of the Board of Directors. Mr. Alan W. Tuck, formerly employed as the Company's President and CEO, remains as a Director of T Cell Sciences. With these changes, T Cell Sciences' senior management now consists of Dr. Ryan, President, COO and CSO, Mr. Grant, Chairman of the Board and CEO, Mr. Norman W. Gorin, (as announced last week) appointed as Vice President, Finance and Chief Financial Officer, Dr. James Levin, Vice President, Development, and Ms. Pamela A. Hay, General Counsel and Secretary. Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits - --------------------------------------------------------------------------- (c) Exhibits 99.1 Press Release issued March 29, 1996 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. T CELL SCIENCES, INC. Date: May 29, 1996 By: /s/ James D. Grant ------------------------------- James D. Grant, Chairman and Chief Executive Officer 4 Exhibit Index ------------- 99.1 Press Release Issued March 29, 1996.
1 NEWS RELEASE - ------------ DATE: FOR IMMEDIATE RELEASE/MAY 29, 1996 CONTACT: Dr. Una S. Ryan James D. Grant President, Chairman of the Board & Chief Operating Officer & Chief Executive Officer Chief Scientific Officer T Cell Sciences, Inc. T Cell Sciences, Inc. (617) 433-0771 (617) 433-0771 T CELL SCIENCES ANNOUNCES CHANGES IN MANAGEMENT NEEDHAM, MA, MAY 29, 1996 -- T Cell Sciences, Inc. (NASDAQ: TCEL) today announced changes in its senior management effective immediately. Dr. Una S. Ryan has been appointed President and Chief Operating Officer and has been elected to the Board of Directors. Dr. Ryan also will retain her position as Chief Scientific Officer. Mr. James D. Grant will assume the position of Chief Executive Officer, in addition to retaining his position as Chairman of the Board of Directors. Mr. Alan W. Tuck, formerly employed as the Company's President and CEO, remains as a Director of T Cell Sciences. With these changes, T Cell Sciences' senior management now consists of Dr. Ryan, President, COO and CSO, Mr. Grant, Chairman of the Board and CEO, Mr. Norman W. Gorin, (as announced last week) appointed as Vice President, Finance and Chief Financial Officer, Dr. James Levin, Vice President, Development, and Ms. Pamela A. Hay, General Counsel and Secretary. "The Board has immense confidence in Una's ability to lead the Company in emphasizing its core strengths, the research and development of novel therapeutics," said Mr. Grant. Dr. Ryan added, "I am looking forward to leading T Cell Sciences. In addition to the Company's leading program in complement inhibition, our research in small molecule T cell inhibitors and in developing a therapeutic vaccine for atherosclerosis provides an exciting new pipeline." T Cell Sciences, Inc., the leader in the development of complement inhibitor therapeutics, is a research-based biotechnology company dedicated to developing pharmaceutical products to regulate inflammatory, T Cell and vascular diseases.